CtrlK
INCY
NASDAQ
Biotechnology
$113.75
USD
+$6.22 (+5.78%)
Last close
Market Cap:
$22.95B
Volume:
3.8M
Previous Close
$107.53
Day Range
$109.47 - $115.56
52 Week Range
$66.83 - $112.29
Average Volume (10 Days)
2.2M
P/E Ratio
17.84
Dividend Yield
0.00%
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
CEO
Mr. Bill Meury
Headquaters
Wilmington, DELAWARE, US
Founded
1993
Employees
2,844
Incyte is acquiring Vega Therapeutics for $1.25 billion upfront to gain access to VGA039, a late-stage drug for severe von Willebrand disease. The deal aims to offset revenue losses from Jakafi's patent expiration in 2028, with analysts projecting the new drug could generate over $1 billion in annual sales by the early 2030s.
0
0
MRNA
Moderna Inc
$67.27
+12.6%
ARWR
Arrowhead Pharmaceuticals Inc
$78.89
-0.5%
NBIX
Neurocrine Biosciences Inc
$168.52
+2.6%
EXEL
Exelixis Inc
$54.77
+2.9%
BIIB
Biogen Inc
$216.03
+7.0%
